header logo image


Page 50«..1020..49505152..6070..»

Cellectis Provides Financial Results for the Second Quarter 2024

August 7th, 2024 2:40 am

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024.

Visit link:
Cellectis Provides Financial Results for the Second Quarter 2024

Read More...

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates

August 7th, 2024 2:40 am

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2024.

Follow this link:
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates

Read More...

ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

August 7th, 2024 2:40 am

LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, August 13, 2024 at 5:00 p.m. ET to discuss its second quarter 2024 financial results and provide a corporate update.

See the original post:
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

Read More...

Travere Therapeutics to Present at Upcoming Investor Conferences

August 7th, 2024 2:40 am

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:

View post:
Travere Therapeutics to Present at Upcoming Investor Conferences

Read More...

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

August 7th, 2024 2:40 am

Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference

Read the rest here:
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

Read More...

BioVie Inc. Announces Reverse Stock Split

August 7th, 2024 2:40 am

Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024 Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024

Read more from the original source:
BioVie Inc. Announces Reverse Stock Split

Read More...

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

August 7th, 2024 2:40 am

– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios’ Pro-Forma Cash Position as of June 30, 2024, to $1.7 Billion –

Here is the original post:
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Read More...

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

August 7th, 2024 2:39 am

TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announces that the Company’s name has been changed from “Aeterna Zentaris Inc.” to “COSCIENS Biopharma Inc.”, effective as of August 6, 2024 (the “Name Change”).

Visit link:
Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

Read More...

Novo Nordisk’s sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024

August 7th, 2024 2:39 am

Bagsværd, 7 August 2024 - Financial report for the period 1 January 2024 to 30 June 2024

See the original post here:
Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024

Read More...

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

August 7th, 2024 2:39 am

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately.

More:
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Read More...

Test your eyesight: Find the odd red plane in under 7 seconds – The Times of India

August 7th, 2024 2:38 am

Test your eyesight: Find the odd red plane in under 7 seconds  The Times of India

Read more from the original source:
Test your eyesight: Find the odd red plane in under 7 seconds - The Times of India

Read More...

What Is Neuropathy? Symptoms, Causes, Diagnosis, Treatment And … – Forbes

July 30th, 2024 2:36 am

Whether nerve damage can be reversed depends on its cause. Removing a tumor that was causing neuropathy, for example, might relieve someone of nerve pain entirely. But some nerve damage is permanent.

Treatments for neuropathy might include lifestyle changes, medications or alternative modalities, such as spinal cord stimulation, says Dr. Rajneesh. The overarching goal is to treat the underlying issue that caused nerves to stop functioning normally, he adds. Forms of neuropathy treatment may include:

Nutritional interventions. Certain nutritional interventions, such as controlling a persons hemoglobin and B12 absorption can help relieve symptoms. If neuropathy is stemming from diabetes, diet and exercise may help decrease a persons hemoglobin A1C (the average of someones blood sugar levels over three months) to a normal range, says Dr. Mayberry. If nutritional interventions are successful, the progression of neuropathy may stop.

Meanwhile, in the case of a person with a B12 deficiency experiencing neuropathy, doctors may administer an injection of B12 every six months, says Dr. Rajneesh, adding that if this deficiency is the cause of an individuals neuropathy, some or all of the nerve damage and symptoms can be reversed.

Physical therapy. Exercise and physical therapy can help retrain damaged nerves to make appropriate connections to muscles, says Dr. Mayberry. This includes use of electrical stimulation, braces, orthoses, compression and other modalities. Improving strength and balance can help increase stability so individuals with neuropathy can maintain balance during daily activities.

Medication. Several medications including anti-seizure medications (pregabalin and gabapentin), antidepressants (like amitriptyline), anxiety medications (like duloxetine) and dementia and Alzheimers medications (like memantine) can help stabilize nerves that are firing haphazardly to reduce pain, as well as prevent abnormal nerve sensations in people with neuropathy, says Dr. Rajneesh.

Certain antidepressants appear to be effective at treating neuropathic pain by helping to increase a persons mobility, adds Dr. Mayberry. If someone has a lot of pain in their feet, they wont be up and moving around, so its a vicious cycle from a symptom management perspective, says Dr. Mayberry. Some antidepressants and anti-epileptics can [enable patients to] exercise and help nerves regenerate.

In some cases if a nerve is irritated or inflamed, a steroid injection may help address this temporarily, as seen in carpal tunnel syndrome and radiculopathies.

Spinal Cord Stimulation. Research demonstrates that spinal cord stimulation can be an effective treatment to prevent pain sensations from reaching the brain, says Dr. Rajneesh. The treatment was approved for neuropathy by the Food and Drug Administration (FDA) in 2021 and involves attaching a stimulating electrode over the spinal cord that blocks pain signals from reaching the brain. A trial course of spinal cord stimulation usually lasts for about a week, and, if its helpful, a permanent stimulator may be surgically placed.

OTC Remedies. Individuals with neuropathy may find relief in supportive shoes and insoles that help with pain and balance issues. Orthopedic shoes and hand or foot braces may also help, as well as some creams containing lidocaine or capsaicin for the feet to help combat painful sensations, says Dr. Mayberry. In terms of diabetic neuropathy, theres some research that a supplement for diabetes, alpha lipoic acid, can improve neuropathy pain.

Transcutaneous Electrical Nerve Stimulation (TENS) Therapy. People who want to avoid taking medications for neuropathy may try TENS (transcutaneous electrical nerve stimulation) therapy, says Dr. Rajneesh. This form of therapy uses electrical impulses to stimulate nerve cells in certain areas and help reduce sensations of pain. TENS units may be more appropriate for focal pain rather than peripheral pain, as peripheral neuropathy might cause discomfort in too large of an area to stimulate with TENS therapy, adds Dr. Rajneesh.

Surgery. Surgery might be appropriate for certain types of neuropathies, such as if a single nerve is being compressed and causing pain or weakness. However, surgical intervention is unlikely to help neuropathy affecting more than one nerve, as is the case in diabetic neuropathy, according to research.

Lifestyle modifications, such as enhanced physical activity and a healthy diet can help prevent nerve damage, says Dr. Mayberry. The Foundation for Peripheral Neuropathy recommends a diet rich in colorful fruits and vegetables, lean protein, legumes and limited salt and alcohol consumption to maintain nerve health. Alcohol can affect nerves negatively and cause dysfunction. Dr. Mayberry also recommends people maintain regular primary care checkups, physical activity and a balanced diet.

Read the original here:
What Is Neuropathy? Symptoms, Causes, Diagnosis, Treatment And ... - Forbes

Read More...

NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline

July 13th, 2024 2:34 am

NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline

View post:
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline

Read More...

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

July 13th, 2024 2:34 am

ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company’s research and development programs.

Here is the original post:
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Read More...

Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th

July 13th, 2024 2:34 am

SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will host a virtual KOL event entitled “Metabolic Rewiring with CB1 Inhibition” on Wednesday, July 24, 2024, at 9:00 AM ET.

Excerpt from:
Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th

Read More...

Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore

July 13th, 2024 2:34 am

This marks the first export into Asia, the 18th international market for Aureus branded products and 21st market for all Avicanna products

See original here:
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore

Read More...

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona’s Patented AAV204…

July 13th, 2024 2:34 am

CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced an agreement by which Beacon will evaluate Abeona's patented AAV204 capsid for the development and commercialization of potential gene therapies for select ophthalmology indications.

Go here to read the rest:
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204...

Read More...

Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational

July 13th, 2024 2:34 am

LAUPHEIM, Germany and MILFORD, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that the company’s new state-of-the-art production line, formerly known as the Rentschler Biopharma Manufacturing Center (RBMC), in Milford, MA in the U.S. is now fully operational. The company has a major project underway at the new line, with several additional projects in the pipeline, and continues to welcome new projects and clients.

Continued here:
Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational

Read More...

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

July 13th, 2024 2:34 am

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance

More here:
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Read More...

Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds

July 13th, 2024 2:34 am

BOCA RATON, Fla., July 11, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (“Entero” or the “Company”) (NASDAQ: ENTO), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,762,674 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.09 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $1,921,315, before deducting financial advisory fees. The reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.

More:
Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds

Read More...

Page 50«..1020..49505152..6070..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick